#United Kingdom #ADC #Piramal Pharma Solutions #Grangemouth

Piramal Pharma Solutions Celebrates a Milestone in Bioconjugate Manufacturing

Piramal Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO), has proudly announced the successful delivery of its 1,500th Antibody-Drug Conjugate (ADC) batch from its facility in Grangemouth, UK. This achievement highlights the company's advanced capabilities, operational efficiency, and technical expertise in the field of bioconjugates.

The 1,500th batch delivered is a commercial lot of an oncology ADC, emphasizing Piramal's commitment to patient-centric solutions in the pharmaceutical industry.

A Legacy of Excellence in ADC Manufacturing

For over 20 years, Piramal Pharma Solutions has been at the forefront of ADC development and manufacturing. As the first FDA-approved CDMO for ADCs, they have an unmatched proficiency in this specialized segment. Their extensive experience spans the entire lifecycle of ADCs, aiding in everything from initial concept validation studies to clinical and commercial-scale manufacturing.

Piramal's facility in Grangemouth plays a pivotal role in the ADCelerate™ program, which aims to streamline and integrate the development and production processes for ADCs. This initiative is designed to capitalize on the specialized capabilities of the Grangemouth site as part of Piramal's global network, ensuring a seamless transition from research and development (R&D) to Good Manufacturing Practice (GMP) compliant production.

Meeting Global Healthcare Needs

The Grangemouth site has been instrumental in producing hundreds of unique bioconjugates and has effectively manufactured 1,500 batches, which include clinical, commercial, and non-GMP lots. Beyond its legacy of manufacturing success, the site benefits from the expertise of its Science Collective team, who provide the technical vision and strategic direction needed to drive projects forward.

Maintaining a strong commitment to quality, the Grangemouth facility possesses a robust regulatory record, including accreditations from both the FDA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). With its unparalleled expertise and advanced solutions, the plant enables Piramal to deliver vital bioconjugates to patients swiftly and with the utmost quality.

About Piramal Pharma Solutions

Piramal Pharma Solutions is dedicated to providing end-to-end development and manufacturing solutions throughout the drug lifecycle. Through a globally integrated network of facilities across North America, Europe, and Asia, Piramal caters to diverse client needs, from drug discovery solutions to commercial manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. They also specialize in high-potency API development, ADCs, and sterile fill-finish services.

In addition, Piramal Pharma Solutions is expanding its capabilities in the biopharmaceutical sector through its collaboration with Yapan Bio Private Limited, enabling the development and manufacturing of biologics, including vaccines and gene therapies.

For further information about Piramal Pharma Solutions, you can visit their website or check their social media profiles on LinkedIn and Facebook.

Conclusion

The recent milestone of delivering the 1,500th ADC batch is a testament to Piramal Pharma Solutions’ dedication to quality, innovation, and addressing global healthcare needs through advanced biopharmaceutical manufacturing.